774243-84-4 Usage
Description
(R)-3-(3-Fluoro-phenyl)-2-hydroxy-propionic acid, with the molecular formula C9H9FO3, is a chiral chemical compound characterized by its non-superimposable mirror image. This versatile molecule features a hydroxy group, a carboxylic acid group, and a fluoro-phenyl group, making it a valuable building block in organic synthesis. Its structural attributes also render it a promising candidate for drug design and development, with potential therapeutic applications in the treatment of inflammation and pain.
Uses
Used in Pharmaceutical Industry:
(R)-3-(3-Fluoro-phenyl)-2-hydroxy-propionic acid is used as a key intermediate in the synthesis of various pharmaceuticals due to its unique structural features and reactivity. Its presence in the molecular structure can influence the pharmacological properties of the final drug product, making it an essential component in drug development.
Used in Drug Design and Development:
In the field of drug design and development, (R)-3-(3-Fluoro-phenyl)-2-hydroxy-propionic acid serves as a potential candidate for creating novel therapeutic agents. Its structural diversity allows for the exploration of various chemical modifications, potentially leading to the discovery of new drugs with improved efficacy and safety profiles.
Used in Treatment of Inflammation and Pain:
(R)-3-(3-Fluoro-phenyl)-2-hydroxy-propionic acid has been studied for its potential therapeutic effects, particularly in the treatment of inflammation and pain. Its molecular composition, which includes a hydroxy group and a carboxylic acid group, may contribute to its ability to modulate biological processes associated with these conditions, offering a promising avenue for the development of new treatments.
Overall, (R)-3-(3-Fluoro-phenyl)-2-hydroxy-propionic acid is a valuable chemical with diverse applications in the pharmaceutical industry, ranging from its use as a building block in organic synthesis to its potential as a therapeutic agent for various medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 774243-84-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,7,4,2,4 and 3 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 774243-84:
(8*7)+(7*7)+(6*4)+(5*2)+(4*4)+(3*3)+(2*8)+(1*4)=184
184 % 10 = 4
So 774243-84-4 is a valid CAS Registry Number.
774243-84-4Relevant articles and documents
MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS
-
Page/Page column 39, (2010/04/30)
The present invention provides conformationally-defined macrocyclic compounds that bind to and/or are functional modulators of the motilin receptor including subtypes, isoforms and/or variants thereof. These macrocyclic compounds, at a minimum, possess adequate pharmacological properties to be useful as therapeutics for a range of disease indications. In particular, these compounds are useful for treatment and prevention of disorders characterized by hypermotilinemia and/or gastrointestinal hypermotility, including, but not limited to, diarrhea, cancer treatment-related diarrhea, cancer-induced diarrhea, chemotherapy-induced diarrhea, radiation enteritis, radiation-induced diarrhea, stress-induced diarrhea, chronic diarrhea, AIDS-related diarrhea, C. difficile associated diarrhea, traveller's diarrhea, diarrhea induced by graph versus host disease, other types of diarrhea, dyspepsia, irritable bowel syndrome, chemotherapy-induced nausea and vomiting (emesis) and post-operative nausea and vomiting and functional gastrointestinal disorders. In addition, the compounds possess utility for the treatment of diseases and disorders characterized by poor stomach or intestinal absorption, such as short bowel syndrome, celiac disease and cachexia. The compounds also have use for the treatment of inflammatory diseases and disorders of the gastrointestinal tract, such as inflammatory bowel disease, ulcerative colitis, Crohn's disease and pancreatitis. Accordingly, methods of treating such disorders and pharmaceutical compositions including compounds of the present invention are also provided.
PHOSPHATE/SULFATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN INTERACTING NIMA (PIN1)
-
Page 82, (2010/02/08)
Phosphate/sulfate ester compounds that modulate and/or inhibit the activity of protein interacting NIMA (PIN1), and to pharmaceutical compositions containing such compounds are described. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating disorders characterized by hypertension, inappropriate cell proliferation, infectious diseases, and neurodegenerative brain disorders, by administering effective amounts of such compounds.
